Lurasidone is NOT approved for unipolar (monopolar) major depressive disorder
Lurasidone is FDA-approved exclusively for bipolar I depression, not for unipolar major depressive disorder (MDD). 1 The FDA label explicitly states that lurasidone is indicated only for "major depressive episode associated with bipolar I disorder" as monotherapy or adjunctive therapy with lithium or valproate—not for standalone unipolar depression.
Why This Distinction Matters
The available guidelines for treating unipolar MDD 2, 3 recommend second-generation antidepressants (SSRIs, SNRIs, bupropion, mirtazapine) as first-line pharmacotherapy, selected based on adverse effect profiles, cost, and patient preferences. Lurasidone is not mentioned in any major depression treatment guidelines because it lacks FDA approval and supporting evidence for this indication.
While research studies 4, 5 have examined lurasidone in patients with "major depressive disorder with mixed features" (subthreshold hypomanic symptoms), these patients represent a distinct population that bridges unipolar and bipolar presentations. The DSM-5 mixed features specifier requires the presence of manic symptoms during a depressive episode, which fundamentally differs from pure unipolar depression.
Clinical Implications
For unipolar MDD without mixed features:
- Use FDA-approved second-generation antidepressants as recommended by ACP guidelines 2
- Start with agents like SSRIs, SNRIs, bupropion, or mirtazapine based on side effect tolerance and patient factors
- Monitor response within 1-2 weeks and modify treatment if inadequate response by 6-8 weeks 2
- Continue treatment 4-9 months after response for first episode; longer for recurrent episodes 2
The Exception: MDD with Mixed Features
If your patient has unipolar MDD plus 2-3 concurrent manic symptoms (elevated mood, increased energy, pressured speech, etc.), lurasidone showed efficacy in research settings 4, 5, 6. However, this represents a gray zone between unipolar and bipolar presentations, and such patients may warrant reconsideration of their diagnosis.
Dosing for Bipolar Depression (FDA-Approved Use Only)
If treating bipolar I depression 1:
- Adults: Start 20 mg once daily with food (≥350 calories); range 20-120 mg/day
- Adolescents (10-17 years): Start 20 mg once daily; maximum 80 mg/day
- Renal impairment (moderate/severe): Maximum 80 mg/day
- Hepatic impairment: Moderate (maximum 80 mg/day); severe (maximum 40 mg/day)
Common Pitfall
Do not prescribe lurasidone for pure unipolar depression simply because it's an "atypical antipsychotic with antidepressant properties." This represents off-label use without supporting evidence or guideline recommendations, and exposes patients to unnecessary metabolic and extrapyramidal side effects (akathisia, weight gain, prolactin elevation) 7, 8 when proven antidepressants are available.